Tuesday , 25 June 2019
Breaking News
Sun Pharma reports interim results from Phase 2 study of interleukin-23

Sun Pharma reports interim results from Phase 2 study of interleukin-23

Sun Pharmaceutical Industries has reported interim results from a Phase 2 study of interleukin-23 (IL-23) inhibitor ILUMYA (tildrakizumab-asmn) in patients with active psoriatic arthritis that was presented in a late-breaking oral presentation at the Annual European Congress of Rheumatology (EULAR 2019) in Madrid, Spain.

The interim analysis revealed that over 71% of patients treated with ILUMYA experienced a 20 percent improvement in joint and skin symptoms (ACR20), meeting the primary endpoint of the study. The interim results showed ILUMYA was well tolerated with a low rate of serious treatment-emergent adverse events.

Sun Pharmaceutical Industries is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.



Download Udaipur Kiran App to read Latest News Today

Leave a Reply

Your email address will not be published. Required fields are marked *

*